Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509700 | 0.90 | TSHR (0.59) | TSHRPTGER4GAAHTTACSS2 | |
| SCHEMBL1543133 | 0.88 | TSHR (0.57) | TSHRPTGER4GAAHTTACSS2 | |
| SCHEMBL13573045 | 0.87 | TSHR (0.57) | TSHRPTGER4GAAHTTACSS2 | |
| SCHEMBL16496427 | 0.85 | TSHR (0.57) | TSHRPTGER4GAAHTTACSS2 | |
| SCHEMBL1542762 | 0.75 | BRD4 (0.53) | TSHRGAAHTTHPGDKMT2A | |
| SCHEMBL1543142 | 0.74 | KDM4E (0.57) | TSHRPTGER4GAAHTTKDM4E | |
| SCHEMBL16176599 | 0.74 | PPARG (0.43) | TSHRGAAHTTTP53RAB9A | |
| SCHEMBL16176989 | 0.74 | TDP1 (0.47) | TSHRHTTTDP1RAB9AMAPT | |
| SCHEMBL13253643 | 0.73 | TSHR (0.47) | TSHRGAAHTTHDAC6RAB9A | |
| SCHEMBL15774434 | 0.73 | PTGER4 (1.00) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | TSHR 3631/4885PTGER4 722/4885GAA 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.